Don Crawford, President & Chief Executive Officer, is a seasoned medical device executive with a proven track record of excellent results driven leadership through team efforts and focused execution. Don previously founded and led Sapheon Inc., a cardiovascular-focused medical device company, from inception to $238 million acquisition by Covidien in 2014. His career started with Medtronic and included sales and marketing positions of increasing responsibility with Guidant Corporation, Ventritex, and Intermedics, including an international sales director role in charge of a $100 million cardiovascular business. Don received his B.Ch.E. in Chemical Engineering from Georgia Tech and M.B.A. from Emory University.

Charles R. Bridges, M.D., Sc.D., Executive Vice President & Chief Scientific Officer, was Chief Technology Officer for the Cardiovascular and Pulmonary Therapeutic Areas at Janssen Pharmaceuticals and the scientific lead on nearly $1 billion of investments and acquisitions. He was previously Professor of Surgery and Bioengineering at the University of Pennsylvania, Chief of Cardiac Surgery at Pennsylvania Hospital, Professor and Chairman of the Department of Cardiothoracic Surgery at Carolina’s HealthCare System. Dr. Bridges has 175 peer-reviewed publications and 15 patents. He received an A.B. in Applied Physics from Harvard University magna cum laude, entering Harvard Medical School at age 18, receiving an M.D. (with honors), an M.S. in Electrical Engineering and a D.Sc. in Chemical Engineering from MIT.

Gabrielle Zaeska, Vice President of Regulatory Affairs & Quality, is an established Regulatory Affairs leader with over 15 years of experience in the medical device industry. Her expertise includes executing regulatory strategy and submissions for the US, EU, and Canada markets, as well as supporting new product applications globally (Australia, Asia, Latin America). Gabrielle began her career in biocompatibility before transitioning into Regulatory Affairs where she formerly led teams at St. Jude Medical and Abbott Laboratories within the Structural Heart divisions. She has also served as a working group member of the International Organization for Standardization (ISO) creating a standard for cardiac occluder devices. Gabrielle received a M.Sc. in Regulatory Affairs from St. Cloud State University and a B.S. in Biology from the University of Minnesota.

Robyn Baek, Vice President of Finance, is a strategic finance leader with extensive experience in accelerating financial success and establishing a data-driven culture. Robyn previously provided financial leadership at SOC Telemed, an acute care telemedicine company through an IPO and three acquisitions. She also serves as an Editorial Board Member of Telehealth and Medicine Today, an international peer-reviewed journal for healthcare leaders and innovators around the globe. Previously, she was an investment banker at Citigroup and a management consultant at Booz Allen Hamilton. Robyn holds a B.S. in Finance from the Wharton School at the University of Pennsylvania and a M.B.A. from the Kelley School of Business at Indiana University.

Horace R. Gillins, Vice President of Clinical Affairs, is a Cardiovascular Invasive Specialist and Certified Clinical Research Professional with over 15 years of healthcare experience and 9 years of experience supporting clinical communications and affairs organizations in interventional cardiology, structural heart, and dermatology. He was previously at Keystone Heart, Inc. as the Director of Clinical Operations, where he managed clinical studies and strategy for the U.S., Canada, and Europe. Before that, Horace was a Sr. Manager of Clinical Affairs at Ulthera, Inc., where his responsibilities included developing and conducting clinical trials, EDC design and development, and product training for commercial and clinical sites. Horace studied Health Promotion at Coastal Carolina University.

Shyam Ramchandani, Ph.D., Vice President of Research, is a serial life sciences entrepreneur with over a decade of drug discovery industry experience, having founded and successfully financed two biopharma ventures. Before his entrepreneurial endeavors, Shyam was a research scientist at Tularik Inc. and Cytokinetics, where he actively participated in preclinical activities, including drug discovery and business development efforts in cancer, immunology, and cardiac muscle biology. Shyam currently serves in adjunct appointments in Ophthalmology and the Smith School of Business at Queen’s University. Shyam has an M.B.A. from Queen’s University and earned his doctorate in Pharmacology and Therapeutics at McGill University with his thesis work being the basis for the founding of MethylGene, a prominent Canadian biopharma company that merged with Mirati Therapeutics.

Jonathan Woodward, CTO and General Manager, A4L, is a seasoned technologist with proven experience in researching, developing, and commercializing electronics and software products for the medical and consumer markets. Jonathan previously was the CTO for Zephyr Technology, a remote physiological monitoring company, where he oversaw product development from inception to commercialization, resulting in a successful acquisition by Covidien/Medtronic in 2015. After the acquisition, Jonathan led research and product development of Home and Hospital remote patient monitoring solutions for the Minimally Invasive Therapies Group at Medtronic. Jonathan has a B.E. in Electrical Engineering from the University of Canterbury, New Zealand.

Ian Shadforth, Vice President and General Manager, has a wealth of experience in the science, strategy, and development of connected health ecosystems comprising medical and consumer hardware integrated with cloud and mobile software. Ian has pioneered a number of cutting-edge programs for large and small companies, including: Johnson and Johnson and GlaxoSmithKline. He was recently co-founder and CEO of AffirmXH Inc., a wearables company working at the intersection of consumer and medical devices.

Ian is a Cambridge-educated scientist with a doctorate in bioinformatics from Cranfield University and an MBA from the University of Dundee. He has been awarded an Enterprise Fellowship by the Royal Society of Edinburgh and the Biotechnology and Biological Sciences Research Council (BBSRC), and the Emerging Chemometrician prize by the Royal Society of Chemistry. He is co-author of the textbook Building Bioinformatics Solutions (Oxford University Press), has authored a number of well-received peer-reviewed scientific publications, and holds numerous patents in the areas of machine learning, diagnostics, and disease management.

Karen McCord, VP, Chief of Staff, is a seasoned executive with experience across several industries, including pharmaceutical, medical device and software. She has experience as a Chief Executive Officer where she led a boot-strapped software company to profitability. While working in the pharmaceutical space, she managed both administrative and technical teams, domestic and internal. She is an active member of MindShare, a network of technology leaders in the Washington, DC region. She is entrepreneurial-minded and skilled in strategic planning, business development, and operations. She completed the University of Pennsylvania's Management and Technology Dual Degree Program with Bachelor degrees from both the Wharton School and School of Engineering and Applied Science.

Stephen has over 15 years of experience in the diagnostics sector of the medical device industry, with experience across various functions, including Quality, R&D, and Operations. He has proven experience in all phases of the medical device lifecycle, from product concept to decommissioning, across multiple jurisdictions, including Europe, the Americas, and Asia.
Stephen has worked extensively with automating and modernizing medical device workflows and Quality frameworks and also has expertise in designing algorithms and machine learning. He holds a BS in Chemistry from Rensselaer Polytechnic Institute.

CorVista provides actionable cardiac diagnostics at the point of care by applying advanced machine learning for more rapid and accurate diagnosis of cardiac disease.
Find Us
United States
3 Bethesda Metro Center,
Suite 700
Bethesda, MD 20814
(833) 267-8478
CorVista Health 2024 | All rights reserved
Privacy PolicyTerms of Use